VivoSeq
Cardiovascular

Cardiac Amyloidosis

2

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Cardiac Amyloidosis is an early-stage landscape with 2 programs across 1 company. The most active players are Idoven 1903 S.L.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Idoven 1903 S.L.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

[68ga]ga-FAPI-46

Nantes University Hospital

Phase 31

[68ga]cbp8 PET/MRI

Brigham and Women's Hospital

Approved
No programs

Analysis

Trial Status

3

clinical trials

Active, not recruiting1 · 33%
Not yet recruiting1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
Active, not recruiting·BBrigham and Women's Hospital·Phase 3·NCT05619302·18 enrolled
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
Not yet recruiting·NNantes University Hospital·Phase 2·NCT07549841·40 enrolled
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)
Recruiting·IIdoven 1903 S.L.·N/A·NCT06978660·2,200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)